Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Cellectar Biosciences, Inc.
Merck Sharp & Dohme LLC
Children's Oncology Group
Dana-Farber Cancer Institute
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
University of Wisconsin, Madison
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Pfizer
Hoffmann-La Roche
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
University of Virginia
University Hospital, Basel, Switzerland
Children's Oncology Group
Bayer
National Cancer Institute (NCI)
AbbVie
Bristol-Myers Squibb
Children's Oncology Group
Novartis
Children's Oncology Group
Acrotech Biopharma Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
City of Hope Medical Center
Columbia University
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Albert Einstein College of Medicine
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
St. Jude Children's Research Hospital
Children's Oncology Group
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
University of Louisville